#United States #Class Action #San Francisco #Hagens Berman #PROCEPT BioRobotics

Lawsuit Filed Against PROCEPT BioRobotics

On August 14, 2026, Hagens Berman Sobol Shapiro LLP announced that they are alerting investors of PROCEPT BioRobotics Corporation (NASDAQ: PRCT) regarding a recently filed securities class action lawsuit. This legal challenge arose due to alarming revelations related to the company's unit handpiece sales performance and excessive inventory levels following aggressive discounting practices.

Background of the Case

The class action lawsuit aims to represent individuals who bought or acquired PROCEPT common stock between February 28, 2024, and February 25, 2026. The allegations revolve around claims that the company, alongside several defendants, violated federal securities laws through misleading communications about its sales performance and business operations.

Investors initially became concerned when the company’s repeated touting of growing sales in its single-use handpieces did not align with the financial distress that surfaced over time. The litigation emphasizes that, unbeknownst to investors, the company engaged in controversial sales practices that involved enticing customers with substantial discounts for large orders, even when these orders exceeded actual demand.

Key Allegations

The lawsuit details a series of partial disclosures that gradually revealed the troubling sales performance of PROCEPT's handpieces, a critical component of their proprietary Aquablation therapy aimed at treating enlarged prostates. The notable points from the case include:

• - On August 6, 2025, the company’s Q2 financial results indicated a significant shortfall in handpiece sales, drastically falling below analysts’ expectations.
• - In November 2025, during the announcement of Q3 results, PROCEPT slashed its sales outlook, citing issues with how it managed customer inventory, suggesting that clients might be maintaining excessive stock levels.
• - A revealing statement was made in February 2026, when the company disclosed that cumulative inventories had exceeded 10,000 units, while handpiece sales had plummeted by 30% sequentially.

These successive revelations led to a staggering decline in the company's stock price—over 48% from August 2025 to February 2026.

Calls to Action for Investors

The firm urges anyone who invested in PROCEPT and suffered significant financial losses to come forward and submit their experiences. Those with pertinent information that can assist in the investigation are encouraged to reach out to Hagens Berman, which focuses on corporate accountability and investor rights. Reed Kathrein, the lead investigator from Hagens Berman, emphasized the importance of transparency in corporate communications and hinted at potential wrongdoing in the company's sales tactics.

Whistleblower Opportunities

The firm also extended a call for whistleblowers. Individuals with non-public information regarding PROCEPT BioRobotics have the opportunity to protect their identities while assisting in the ongoing investigation. The SEC Whistleblower program offers rewards of up to 30% for individuals who provide actionable intelligence that results in government recoveries.

About Hagens Berman

Hagens Berman Sobol Shapiro LLP is known for its complex litigation work protecting the rights of shareholders, consumers, and various groups affected by corporate malpractice. The firm has successfully recovered over $2.9 billion for its clients and continues to advocate vigorously for justice and accountability within corporate America. Investors are encouraged to stay updated on developments regarding this case and seek guidance on further steps they can take.

For more information, or if you're an investor affected by this situation, reach out to Hagens Berman at [email protected] or call 844-916-0895.